The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with Itraconazole in patients with locally adcvanced esophageal squamous cancer
Esophageal cancer is one of the most lethal malignancies. Esophageal squamous cell carcinoma (ESCC) is the predominant type in China, accounting for over 90% of all esophageal cancer. Concurrent chemoradiation therapy (CCRT) remains the standard therapy of locally advanced ESCC. However, the outcome remains poor.
The aberrant activation of Hedgehog (HH) signaling is associated with a variety of human malignancies. Previous studies found that the reactivation of HH pathway occurs in 60% of esophageal cancer. Targeting the Hh pathway for cancer therapy was expected to work wonders in Hh-dependent cancers. Itraconazole, an antifungal agent, has been shown to inhibit the Hh and AKT signaling pathways.
The aim of our study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with Itraconazole in patients with locally adcvanced esophageal squamous cancer
| Condition | Esophageal Diseases, Esophageal Disorders, Esophageal Cancer, Esophageal Cancer, Squamous cell carcinoma, Squamous cell carcinoma, GASTROINTESTINAL DISORDER, Gastrointestinal Diseases and Disorders, head and neck cancer, head and neck cancer, Gastrointestinal Diseases and Disorders, Esophageal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Esophagus, Esophageal Disorders |
|---|---|
| Treatment | Itraconazole |
| Clinical Study Identifier | NCT04481100 |
| Sponsor | Hangzhou Cancer Hospital |
| Last Modified on | 22 September 2023 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.